key: cord-0921710-mzae18lt authors: Zheng, Zhetao; Wang, Yu; Wu, Xuesheng; Zhang, Haoran; Chen, Hongmin; Lin, Haishuang; Shen, Yuxuan; Xia, Qing title: Engineering RNA viruses with unnatural amino acid to evoke adjustable immune response in mice date: 2021-12-07 journal: bioRxiv DOI: 10.1101/2021.12.04.471206 sha: fda19375ac2dc8714272a5148c6f784b98a9db7f doc_id: 921710 cord_uid: mzae18lt Ribonucleic acid (RNA) viruses pose heavy burdens on public-health systems. Synthetic biology holds great potential for artificially controlling their replication, a strategy that could be used to attenuate infectious viruses but is still in the exploratory stage. Herein, we used the genetic-code expansion technique to convert Enterovirus 71 (EV71), a model of RNA virus, into a controllable EV71 strain carrying the unnatural amino acid (UAA) Nε-2-azidoethyloxycarbonyl-L-lysine (NAEK), which we termed an EV71-NAEK virus. EV71-NAEK could recapitulate an authentic NAEK time- and dose-dependent infection in vitro and in vivo, which could serve as a novel method to manipulate virulent viruses in conventional laboratories. We further validated the prophylactic effect of EV71-NAEK in two mouse models. In susceptible parent mice, vaccination with EV71-NAEK elicited a strong immune response and potentially protected their neonatal offspring from lethal challenge similar to that of commercial vaccines. Meanwhile, in transgenic mice harboring a PylRS-tRNAPyl pair, substantial elements of genetic-code expansion technology, EV71-NAEK evoked an adjustable neutralizing-antibody response in a strictly external NAEK dose-dependent manner. These findings suggested that EV71-NAEK could be the basis of a feasible immunization program for populations with different levels of immunity. Moreover, we expanded the strategy to generate controllable coxsackieviruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for conceptual verification. In combination, these results could underlie a competent strategy for attenuating viruses and priming the immune system via artificial control, which might be a promising direction for the development of amenable vaccine candidates and be broadly applied to other RNA viruses. the nascent viral polypeptide at the desired positions, which are selected by massive 48 random mutations with undefined rules 18 , impeding the approach expanded to other 49 emerging viruses. Moreover, UAA modification is a switch that enables artificial 50 control of virus replication 19,20 , hinting at a potential strategy of precisely controlling 51 viral replication in vivo to imprint desired antibody landscapes. 52 We applied the genetic-code expansion technique to modify Enterovirus 71 (EV71) as In vitro UAA-controllable RNA virus-packaging and -production system 63 In this study, we chose EV71, the major pathogen in hand-foot-mouth disease (HFMD) 64 in children and infants 24,25 , as a model virus to test the feasibility of a production translation machinery (Fig. 1b, c) . In addition, we observed that the machinery's 83 introduction did not significantly affect cell proliferation in either line, which was 84 beneficial for viral packaging and propagation (Fig. 1d) . 85 After establishing appropriate viral-packaging systems in the stable cell lines, we patterns similar to those of HEK293T cells, which differed significantly from those of 90 EV71-infected HEK293T cells (Fig. 1e, f) . The Venn diagram (Fig. 1g) to those of HEK293T cells, which in turn were very different from those of EV71-96 infected HEK293T cells (Fig. 1h) . Gene Ontology (GO) terms and Kyoto Encyclopedia 97 of Genes and Genomes (KEGG) signaling pathways further indicated their common 98 application of stable cell line ± NAEK groups for generating artificial viruses from 99 other extant RNA viruses (Fig. 1i, Extended Data Fig. 2a, b) . The WTA results were 100 similar in the NAEK-Vero stable cell line (Extended Data Fig. 3 ). A guideline for identifying optimal amber-codon introduction into the viral genome 108 based on reliable NAEK incorporation machinery is pivotal to an effective NAEK-109 controllable viral-replication system. Therefore, we profiled the entire viral genome by 3B, 5 of 5 in 3C, and 9 of 10 in 3D) whose NAEK-controllable virus could be 115 successfully packaged and propagated, we noted that viruses in 3C or 3D genes showed 116 prevalently higher viral titers (Fig. 2a, Extended Data Fig. 4) . To assess the features 117 of incorporated positions that could affect viral titer, we further tested 15 and 20 mutant 118 codons located in particular EV71-3C and 3D genes, respectively (Fig. 2b, c) . We thus 119 generated 9 and 11 variants, respectively, with virions of 10 4 -10 6.5 TCID50/mL, and 120 6 clearly observed NAEK-dependent cytopathic-effect (CPE) phenotypes as expected 121 (Fig. 2d, Extended Data Fig. 5) . 122 These results indicated that incorporating UAA to replace amino acids with similar 123 properties (NAEK to lysine or glycine) and appropriate conservation could increase the 124 production efficiency and genomic fidelity of controllable viruses (Extended Data Fig. 125 6a-c). Of the 35 incorporation positions screened in this study, 30 residues were located 126 on the surface of 3C/3D, and the other five were inaccessible to the solvent (Extended 127 Data Fig. 7) . Furthermore, surface sites might be more open to NAEK with respect to 128 amino acid similarity (Extended Data Fig. 6a-c) . Other factors, such as residue-129 residue interaction or steric effects, also affected overall package efficiency to some propagation of EV71-3D-E105NAEK was NAEK dependent (Fig. 2e) . Compared with 162 that of WT EV71, the growth curve of EV71-3D-E105NAEK further demonstrated that 163 NAEK-controllable viral replication was well established in vitro (Fig. 2f) . Moreover, 164 transmission electron microscopy (TEM) showed no significant differences in 165 morphologies, implying that EV71-3D-E105NAEK maintained the original phenotype 166 of parental EV71 (Fig. 2g) . Owing to its combined high viral titer and low escape 167 frequency, we chose EV71-3D-E105NAEK as a model strain for further study in vivo. Efficacy, safety, and protective evaluation of EV71-3D-E105NAEK as a vaccine 170 candidate in vivo 171 Next, we evaluated the in vivo safety and immunogenicity of intraperitoneally (i.p.) injected EV71-3D-E105NAEK in adult BALB/c mice, using commercial Sinovic-173 EV71 vaccine as positive control (Fig. 3a) . No adult mice died from EV71-3D- E105NAEK or showed obvious body weight (BW) loss or other health issues due to 175 this injection (Fig. 3b, c) . We detected no significant differences in viral load in the 176 brain or skeletal muscle between the EV71-3D-E105NAEK and Sinovic-EV71 groups, 177 and even less viral load in small intestine was observed in EV71-3D-E105NAEK mice 178 than in Sinovic-EV71 mice, indicating the good in vivo safety of EV71-3D-E105NAEK 179 as a vaccine candidate (Fig. 3d) . Two weeks after single-or double-dose immunization, and Sinovic-EV71 vaccines (Fig. 3g) , with no significant BW loss (Fig. 3h ). In addition, 187 viral load in the small intestine, brain, and spinal cord in both the EV71-3D-E105NAEK 188 and Sinovic-EV71 groups was significantly lower than in the vehicle group (Fig. 3i) , 189 indicating the protective efficacy of EV71-3D-E105NAEK in neonatal mice. The success of this viral-engineering strategy (1) Herein we reported that the established two-round viral-engineering system, consisting The wild type EV71 generated from reverse genetic system was performed as previous Expression of animal virus genomes Accelerating Next-Generation Vaccine Development for Global 576 The COVID-19 vaccine development landscape Developing Covid-19 Vaccines at 580 Pandemic Speed Artificial riboswitches for gene expression and replication control 582 of DNA and RNA viruses Tunable and reversible drug control of protein production via a 584 self-excising degron Photocontrollable mononegaviruses Chemogenetic ON and OFF switches for RNA virus replication Immunological considerations for COVID-19 vaccine 590 strategies Vaccine development for 592 emerging infectious diseases Rapid reconstruction of SARS-CoV-2 using a synthetic 594 25 genomics platform An Infectious cDNA Clone of SARS-CoV-2 Systems vaccinology of the BNT162b2 mRNA vaccine in 598 humans Anti-SARS-CoV-2 receptor binding domain antibody evolution after 600 mRNA vaccination An Expanded Eukaryotic Genetic Code Expanding the Genetic Code 604 of Escherichia coli Construction of a Live-Attenuated HIV-1 Vaccine through Genetic 606 Code Expansion Generation of influenza A viruses as live but replication-incompetent 608 virus vaccines Restoration of dystrophin expression in mice by suppressing a 610 nonsense mutation through the incorporation of unnatural amino acids Controlling the Replication of a Genomically Recoded HIV-1 with 613 a Functional Quadruplet Codon in Mammalian Cells A trans-complementation system for SARS-CoV-2 recapitulates replication without virulence Replication and single-cycle delivery of SARS-CoV-2 618 replicons A guide to vaccinology: from basic principles to new 620 developments Clinical 622 features, diagnosis, and management of enterovirus 71 Virology, epidemiology, pathogenesis, and control of enterovirus 625 71 Genetic Code Expansion in Animals Expanding and reprogramming the genetic code of cells and animals Heritable expansion of the genetic code in mouse and zebrafish Methoxyphenols as Convenient Oxidative Bioconjugation Reagents with Application to Site-Selective Heterobifunctional 634 Rapid Chemoselective Bioconjugation through Oxidative 636 Coupling of Anilines and Aminophenols Precise Photoremovable Perturbation of a Virus-Host 639 Broadening the versatility of lentiviral vectors as a tool in nucleic 641 acid research via genetic code expansion A Versatile Tool for Live-Cell Imaging and Super-Resolution 643 Nanoscopy Studies of HIV-1 Env Distribution and Mobility Minimal Tags for Rapid Dual-Color Live-Cell Labeling and Super-646 Resolution Microscopy Directed Evolution: Methodologies and Applications Vero cell upstream bioprocess development for the 650 production of viral vectors and vaccines Playing with the Molecules of Life A Precise Chemical Strategy To Alter the Receptor Specificity 654 of the Adeno-Associated Virus Site-Specific PEGylated Adeno-Associated Viruses with Increased 656 Serum Stability and Reduced Immunogenicity A. mRNA vaccines for infectious 658 diseases: principles, delivery and clinical translation Childhood vaccines and antibiotic use in low-and middle-income countries Phase I/II study of COVID-19 RNA vaccine BNT162b1 in 664 adults Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in 666 pregnancy Engineering living therapeutics with synthetic biology Processing of a cellular 670 polypeptide by 3CD proteinase is required for poliovirus ribonucleoprotein 671 complex formation Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A 674 Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label Red dots indicate upregulated genes; blue dots downregulated genes Two biological replicates were used per sample. (f) PCA of HEK293T±NAEK Venn diagram showing significant overlap (P < 0.005) of DEGs 697 among HEK293T cells, engineered packaging systems, and EV71-infected HEK293T 698 cells. (h) Hierarchical-clustering and heatmap analysis of DEGs in HEK293T cells, the 699 engineered packaging systems, and EV71-infected HEK293T cells. (i) Representative 700 GO terms and KEGG enrichment analysis of the engineered HEK293T+NAEK 710 (e) CPE of EV71-3D-E105NAEK packaged with the HEK293T-NAEK system and 711 produced by the VeroE6-NAEK system in the presence or absence of NAEK. Scale bars, 712 50 μm. (f) Growth kinetic curves of EV71-3D-E105NAEK generated by the NAEK 713 system in the presence or absence of NAEK at indicated time points Evaluation of the EV71-3D-E105NAEK virus's safety, immunogenicity, 719 and protection levels. (a) Schematic of study design. To evaluate safety and 720 immunogenicity, 4-week-old female BALB/c mice were first injected i day-old offspring of 722 immunized BALB/c mice received i.p. injections of a lethal EV71 strain (SD059) for 723 14 days. (b, c) Survival rates and BW changes in BALB/c mice. (d) Viral RNA copies 724 detected in the small intestine, brain, and skeletal muscle. (e, f) IgG and IgM titers 725 detected before and after one or two doses of immunization. (g, h) Survival rates and 726 BW changes in neonatal child BALB/c mice. (i) Detection of viral RNA Sinovic-EV71 vaccine. (j, k) Fluorescent images and H&E staining 729 of small intestines of neonatal mice at day 14. Scale bars, 200 μm. Data in (b-i) are 730 presented as mean ± SD (n = 5). Two-way analysis of variance (ANOVA) and Tukey's Immune response to UAA-controllable EV71-3D-E105NAEK in 735 transgenic mice. (a) Transgenic mice harboring the UAA incorporation system were 736 first injected i.p. with EV71-3D-E105NAEK for 14 days in the presence or UAA. (b) WB analysis of PylRS and GFP 39TAG expression in transgenic mice Quantitative RT-PCR (qRT-PCR) analysis of tRNA Pyl levels in transgenic mice 741 (e, f) Fluorescent images and H&E staining of the small intestines of neonatal mice on 742 day 14. Scale bars, 200 μm. (g, h) Survival rates and BW changes in transgenic mice 743 after inoculation with EV71-3D-E105NAEK. (i) IgG and IgM titers detected after 744 immunization with EV71-3D-E105NAEK in the presence of low-, medium-, or high-745 dose UAA, indicating in the UAA dose-dependent manner. Data (d, g-i) are presented 746 as mean ± SD (n = 5). Two-way ANOVA Extended Data Figure 1. Establishment of the VeroE6-tRNA pyl /PylRS/GFP 39TAG 753 stable cell line. (a) Plasmid of the UAA incorporation system and stable cell line 754 screening. (b) Comparison of transfection efficiency at different voltages Number of green fluorescent protein (GFP)-positive cells and rate of relative 756 luminescence at different voltages. (e) GFP fluorescence appeared in the screened stable 757 cell line in a NAEK-dependent manner. Scale bars, 50 μm. (f) PCR analysis of PylRS 758 and GFP expression in the stable cell line Extended Data Figure 2. Representative GO terms and KEGG enrichment analysis of 762 HEK293T+NAEK cells and the engineered packaging systems compared with Whole-transcriptome analysis of Vero cells and the 767 engineered production systems. (a) Plots show whole-transcriptome FPKMs. Red 768 dots indicate upregulated genes; blue dots downregulated genes. Two biological 769 replicates were used per sample. (b) PCA of Vero cells and the engineered production 770 systems. (c) Hierarchical-clustering and heatmap analysis of DEGs in Vero cells and 771 the engineered production systems. (d) Venn diagram showing significant overlap Extended Data Figure 4. CPE of EV71-NAEK virus harboring an amber codon at 776 VP1-VP4, 2A-2C, and 3A-3D by random-site selection. Scale bars Extended Data Figure 5. CPE imaging of EV71-NAEK strains produced by the 781 NAEK incorporation system in the presence or absence of NAEK. Day X represents 782 days required to attain ~100% CPE (n = 3). (a) Strains with NAEK incorporated into 783 3C protein. (b) Strains with NAEK Guideline for and validation of NAEK-controllable virus 787 design for other single-stranded RNA (ssRNA) viruses. (a-c) Relationship between 788 viral titers and residue location, and conservation or similarity of amino acids Workflow for the guideline for and validation of controllable virus design Blue circles indicate the detected 792 probability (0 or 1) of successful viral packaging, red circles the predicted probability 793 thereof. Four factors were selected for logistic regression for function and related 794 estimates. Predicted probability of success or failure per group was also plotted (mean 795 ± standard error of the mean PDB: 4GHQ). (b) Residues on 3C surface are 802 highlighted in magenta. (c) Residues located within 3C are shown in the sphere PDB: 3N6L). (e) Residues on 3D surface are 804 highlighted in orange. (f) Residues located within 3D are shown in the sphere 566 The authors declare no competing financial interests. Correspondence and requests for materials should be addressed to Q. X.